Fig 1.
LD–loading dose, PFA–platelet function assessment. Times displayed are medians and IQRs. *The median baseline PFA time was 2 minutes after procedure start (IQR -1 to 6). **The median residual PFA1 time was 0 minutes post procedure (IQR 0 to 2). Missing data were as follows: 1 patient was missing flow time; 5 patients were missing baseline PFA times; 4 patients were missing residual PFA1 times; 8 patients were missing residual PFA2 times; 8 patients were missing residual PFA3 times; 17 patients were missing residual PFA4 times.
Table 1.
Baseline clinical and demographic characteristics.
Table 2.
Angiographic and procedural characteristics.
Fig 2.
ADP platelet reactivity profile.
Panel A—Median ADP receptor platelet activity profile in first 24 hours post-presentation with STEMI and treatment with PPCI. Red markers identify platelet response for the four acute ST patients (dotted line indicates the high residual platelet reactivity threshold of 46.8 U for ADP-test). Panel B–The profile of high residual platelet activity, in the first 24 hours, following administration of a 60 mg Prasugrel loading dose at the time of PPCI.
Fig 3.
Effect of door to end of procedure time and baseline ADP platelet activity on ADP platelet function in the first 24 hours post-presentation with STEMI and treatment with PPCI.
Fig 4.
Influence of pre-procedural opiate and anti-emetic treatment on platelet function in the first 24 hours post-presentation with STEMI and treatment with PPCI.
ADP: morphine effects pre-PPCI p = 0.56, end of PPCI p<0.001, 1 hour post-PPCI p = 0.035, 2 hours post-PPCI p = 0.007, 24hours post-PPCI p = 0.16; morphine x time interaction p<0.001. ASPI: morphine effect p = 0.67; morphine x time interaction p = 0.36. TRAP: morphine effect p = 0.08; morphine x time interaction p = 0.30. U44619: morphine effect p = 0.43; morphine x time interaction p = 0.82.